GGrantIndex
Sort

10,766 grants matching checkpoint inhibitor

Modulation of Microglia and T Cell Interactions in Malignant Glioma

$287,999
Amy Beth Heimberger · Northwestern University At Chicago · R01 · FY2023 · CA

Modulation of Microglia and T Cell Interactions in Malignant Glioma

$287,999
Amy Beth Heimberger · Northwestern University At Chicago · R01 · FY2025 · CA

Project 1

$287,916
Ann G Schwartz · Wayne State University · P20 · FY2023 · CA

Targeted Therapy for Endometrial Cancer

$287,850
Kimberly K Leslie · University Of New Mexico Health Scis Ctr · R01 · FY2023 · CA

Cyclin-Dependent Kinase Inhibition During S Phase

$287,802
Geoffrey I Shapiro · Dana-Farber Cancer Inst · R01 · FY2013 · CA

Mechanisms that coordinate cell size with mitotic entry

$287,688
James B Moseley · Dartmouth College · R01 · FY2013 · GM

Modulators of p53 Expression and Function

$287,640
Cleveland Clinic Lerner Col/Med-Cwru · R01 · FY2005 · CA

Modulators of p53 Expression and Function

$287,640
Cleveland Clinic Lerner Col/Med-Cwru · R01 · FY2003 · CA

Modulators of p53 Expression and Function

$287,640
Cleveland Clinic Lerner Col/Med-Cwru · R01 · FY2004 · CA

Islet Growth Factors Transgenic and Viral Modeling

$287,606
Andrew F. Stewart · University Of Pittsburgh At Pittsburgh · R01 · FY2007 · DK

Human Translational Studies of Vascular Thrombosis and Inflammation

$287,073
Yogendra Kanthi · National Heart, Lung, And Blood Institute · ZIA · FY2021 · HL

HTLV-I Tax activates the anaphase promoting complex

$286,847
Chou-Zen Giam · Henry M. Jackson Fdn For The Adv Mil/Med · R01 · FY2010 · CA

Targeting Unique Meyloid Populations to Overcome Anti-PD-1 Resistance Conferred by Specific Cancer Mutations

$286,658
Brian C Miller · Univ Of North Carolina Chapel Hill · K08 · FY2024 · CA

Targeting Unique Meyloid Populations to Overcome Anti-PD-1 Resistance Conferred by Specific Cancer Mutations

$286,658
Brian C Miller · Univ Of North Carolina Chapel Hill · K08 · FY2023 · CA

Project 2: Discovery and validation of novel molecular and immune predictors of colorectal cancer mortality and response to treatment in racially and ethnically diverse patient populations

$286,521
Christopher I Li · Fred Hutchinson Cancer Center · P50 · FY2024 · CA

The role of DNA damage response in chronic kidney disease

$286,411
Rannar Airik · University Of Pittsburgh At Pittsburgh · R01 · FY2022 · DK

Regulation of Replication Checkpoint by Proteolysis

$286,125
Yale University · R01 · FY2005 · CA

Regulation of Replication Checkpoint by Proteolysis

$286,125
Yale University · R01 · FY2004 · CA

The integrated stress response and the microenvironment in melanoma progression

$285,994
Constantinos Koumenis · University Of Pennsylvania · R01 · FY2025 · CA

Administrative/Clinical Trials Core

$285,935
Kirby I Bland · University Of Alabama At Birmingham · P50 · FY2007 · CA

Project 2

$285,839
Rory Smoot · Mayo Clinic Rochester · P50 · FY2025 · CA

STINGing GBM: A First-in- Man Clinical Trial in Surgical Resectable Recurrent GBM

$285,775
Amy Beth Heimberger · Northwestern University At Chicago · P50 · FY2023 · CA

Intestinal Cell Growth Control: Role of Tyrosine Kinases

$285,680
Christine Ann Cartwright · Stanford University · R01 · FY2008 · DK

Intestinal Cell Growth Control: Role of Tyrosine Kinases

$285,680
Christine Ann Cartwright · Stanford University · R01 · FY2009 · DK

Selective Sensitization of Pancreatic Cancer to Therapy by Chk1 and PARP1 Inhibit

$285,608
Meredith A Morgan · University Of Michigan At Ann Arbor · R01 · FY2013 · CA